Session Information
Date: Saturday, October 6, 2018
Session Title: Parkinson’s Disease: Clinical Trials, Pharmacology And Treatment
Session Time: 1:45pm-3:15pm
Location: Hall 3FG
Objective: The objective this report is to describe collected outcomes from a large scale registry of a Deep Brain Stimulation (DBS) system capable of Multiple Independent Current Source Control (MICC) in the management of symptoms of levodopa-responsive Parkinson’s disease (PD).
Background: The effectiveness of Deep Brain Stimulation (DBS) for reducing motor complications of Parkinson’s disease (PD) has been substantiated by randomized controlled trials (Schuepbach et al.,2013). Additionally, motor improvement is sustained for up to 10 years (Deuschl et al. 2013). Large patient data registries may facilitate insights regarding real world, clinical use of DBS. Furthermore, no registry database currently exists for a multiple-source, constant current DBS system.
Methods: The Vercise DBS Registry is a prospective, on-label, multi-center, international registry sponsored by Boston Scientific Corporation. The Vercise DBS system (Boston Scientific) is a multiple-source, constant-current system. Subjects were followed up to 3 years post-implantation where their overall improvement in quality of life and PD motor symptoms was evaluated. Clinical endpoints evaluated at baseline and during study follow included Unified Parkinson’s disease Rating Scale (UPDRS), MDS-UPDRS, Parkinson’s disease Questionnaire (PDQ-39), and Global Impression of Change.
Results: To date, 290 patients have been enrolled in the registry and this report will provide an overview of the data collected so far from implanted patients within this cohort. At 1 year post-implant, 36.2% improvement in MDS-UPDRS III scores (stim on/meds off) compared with baseline was reported. This improvement in motor function was supported by an improvement in quality of life as assessed by PDQ39 Summary Index (5.6 point improvement, n =146) at 1 year. Roughly 90% of patients and clinicians reported improvement as compared with Baseline.
Conclusions: This DBS registry represents the first comprehensive, large scale collection of real-world outcomes and evaluation of safety and effectiveness of a multiple-source, constant-current DBS system.
References: 1) Schuepbach WM., et al. N Engl J Med. 2013 Feb 14;368(7):610-22. 2) Deuschl G. and Agid Y. Lancet Neurol. 2013 Oct;12(10):1025-34.
To cite this abstract in AMA style:
G. Deuschl, R. Jain, H. Scholtes, A. Wang, M. Barbe, S. Paschen, A. Andrea Kühn, M. Pötter-Nerger, J. Volkmann, J. Vesper. Outcomes of a Prospective, Multi-center International Registry of Deep Brain Stimulation for Parkinson’s Disease [abstract]. Mov Disord. 2018; 33 (suppl 2). https://www.mdsabstracts.org/abstract/outcomes-of-a-prospective-multi-center-international-registry-of-deep-brain-stimulation-for-parkinsons-disease/. Accessed November 22, 2024.« Back to 2018 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/outcomes-of-a-prospective-multi-center-international-registry-of-deep-brain-stimulation-for-parkinsons-disease/